SGMO Sangamo: Forward P/E Multiple

Graphic logo of Sangamo BioSciences (SGMO)

Sangamo Therapeutics (SGMO) specializes in developing innovative DNA-based drugs. The business relies on a unique staff of zinc finger experts with minimal employee turnover, while simultaneously engaging in a fierce patent battle with the wealthiest biotech behemoths. This chart for the stock on GURU.Markets confirms these data, recording a P/E ratio of 0.00, which underscores market expectations for the company's success in therapy.

Projected Price to Earnings: Sangamo Therapeutics, Inc. (SGMO) for 07/04/2022 - 05/09/2026

Financial and market metric breakdowns for Sangamo Therapeutics, Inc. (SGMO)

- company stock capitalization data:
Summary company analysis:Sangamo
Product sample of sangamo.com

The forward P/E serves as a tool for comparing an asset's current value with its projected earnings. This metric is calculated as the ratio of the market price to the expected net income for the cycle. By analyzing the issuer's forward P/E, an investor determines the extent of the expectations already priced in. For Sangamo Therapeutics (SGMO), the volatility of this indicator reflects development risks. Outsourcing vector production reduces capital expenditures, thereby impacting the final assessment of business efficiency.

Direct competitors

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple